Abstract: The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.
Type:
Application
Filed:
November 21, 2023
Publication date:
March 21, 2024
Inventors:
Audrey JEANJEAN, Danielle COMBESSIS, David RIGAL, Chris HO, Pankaj TANEJA
Abstract: Compositions, methods and uses are disclosed herein for treating male and female hidradenitis suppurativa with anti-androgen medications. Clinical examples of treatment of hidradenitis suppurativa with proxalutamide are provided. The methods, uses and composition described can be applied as treatment to mitigate an outbreak of hidradenitis suppurativa or as a prophylactic to prevent the occurrence of hidradenitis suppurativa.
Abstract: The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.
Type:
Application
Filed:
September 1, 2023
Publication date:
March 21, 2024
Applicant:
Minoryx Therapeutics S.L.
Inventors:
Marc MARTINELL PEDEMONTE, Maria Pilar PIZCUETA LALANZA, Estefania TRAVER LOPEZ, Ana Maria GARCÍA COLLAZO, Maria Angeles PÉREZ DE LA CRUZ MORENO
Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
Type:
Application
Filed:
January 29, 2021
Publication date:
March 21, 2024
Inventors:
David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
Abstract: Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
Type:
Application
Filed:
May 23, 2023
Publication date:
March 21, 2024
Applicants:
DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL
Inventors:
Nathanael S. Gray, Stephen J. Haggarty, Quan Cai, Tinghu Zhang, Maria Catarina Telo Baptista Lima da Silva, Fleur M. Ferguson
Abstract: The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.
Type:
Application
Filed:
January 21, 2022
Publication date:
March 21, 2024
Applicants:
TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, MEDIZINISCHE HOCHSCHULE HANNOVER
Inventors:
Svenja SAKE, Sibylle HAID, Jessica RÜCKERT, Thomas SCHULZ, Thomas PIETSCHMANN
Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.
Type:
Application
Filed:
November 7, 2023
Publication date:
March 21, 2024
Inventors:
John CHAN, Keith Try UNG, Mei-Chang KUO, John Nigel Pritchard
Abstract: The present disclosure provides oral suspension formulations of drotaverine or a salt thereof, methods of their preparation, and their use in treatment.
Abstract: Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (SGRM) are disclosed. The AR antagonist may be enzalutamide. The SGRM may be an octahydro fused azadecalin compound, such as exicorilant, ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone which has the structure: The AR antagonist and the SGRM may be administered once per day, and may be administered with food. Enzalutamide doses may be 150-200 mg/day, e.g., 160 mg/day. Exicorilant doses may be 100-350 mg/day, e.g., 240 mg/day, or 280 mg/day, or 320 mg/day.
Type:
Application
Filed:
August 29, 2023
Publication date:
March 21, 2024
Applicant:
Corcept Therapeutics Incorporated
Inventors:
Grace Mann, Joseph Custodio, Iulia Cristina Tudor, Andrew Greenstein
Abstract: Disclosed herein are compounds, compositions, and methods for inhibiting HECT E3 ubiquitin ligases. In some embodiments, the compounds are formulated as a pharmaceutical composition and administered to a subject in need thereof. In some embodiments, the subject in need thereof is diagnosed with a neurological disease or a cancer characterized by increased or ectopic HECT E3 ligase activity.
Type:
Application
Filed:
January 21, 2022
Publication date:
March 21, 2024
Inventors:
Hiroaki Kiyokawa, Rama K. Mishra, Chi-Hao Luan
Abstract: The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.
Type:
Application
Filed:
March 3, 2022
Publication date:
March 21, 2024
Inventors:
Shane LIDDELOW, Kevin GUTTENPLAN, Ben BARRES (Deceased)
Abstract: This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure for indications such as, but not limited to, traumatic brain injury and stroke.
Type:
Application
Filed:
September 26, 2023
Publication date:
March 21, 2024
Applicant:
Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)
Inventors:
Pierre VANKAN, Andreea SASARMAN, Grasiela Bourscheit WILLMBRINK
Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
Abstract: The present invention relates to a pharmaceutical composition comprising the calcium; {4-[(5,6-diphenylpyrazin-2-yl) (propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process to produce it.
Type:
Application
Filed:
January 28, 2022
Publication date:
March 21, 2024
Inventors:
Katie AMSSOMS, Eddy DE PROOST, Wenyu DONG, Paul HARTMAN KOK, Rene HOLM, Kristof KIMPE, Greet MEURS, Maxim VERSTRAETEN
Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
Type:
Application
Filed:
April 26, 2023
Publication date:
March 21, 2024
Inventors:
Sergio A. Gradilone, Nicholas F. LaRusso
Abstract: Provided herein are compositions of matter, e.g. solid forms, pharmaceutical compositions, pharmaceutical combinations and unit dosage forms, of a compound of the following structural formula: (I) or a pharmaceutically acceptable salt thereof, or a hydrate of either of the foregoing. The compositions of matter described herein can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and/or conditions.
Type:
Application
Filed:
January 4, 2022
Publication date:
March 21, 2024
Inventors:
J. Micah Wilcox, Jason Marc Foulks, Steven L. Warner
Abstract: The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease.
Type:
Application
Filed:
November 7, 2023
Publication date:
March 21, 2024
Inventors:
Lucio Claudio Rovati, Gianfranco Caselli, Emanuele Sala
Abstract: The present invention relates to compositions, formulations, and methods for treating drug-induced ILF/IPF disorders by administration of a UPase inhibitor, with or without supplemental uridine, a uridine prodrug or a uridine mimetic to a subject in need thereof. Candidate drugs for the treatment include bleomycin and analogs, methotrexate and analogs, and amiodarone and analogs.
Type:
Application
Filed:
September 1, 2023
Publication date:
March 21, 2024
Inventors:
William A. Garland, Philip Liaw, Brian D. Frenzel
Abstract: Use of a pyrido[1,2-a]pyrimidone analogue. Specifically disclosed is use of a compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing cancers in the digestive tract system. The compound I or the pharmaceutically acceptable salt thereof has good antitumor activity against one or more of head and neck cancer, hepatocellular cancer, colorectal cancer, esophageal cancer, gastric cancer and nasopharyngeal cancer.
Abstract: The present disclosure provides uses for a KRASG12C inhibitor, such as the compound of Formula I (AMG 510, sotorasib) in treating cancers, such as non-small cell lung cancer, in subjects with certain characteristics.
Type:
Application
Filed:
January 7, 2022
Publication date:
March 21, 2024
Inventors:
Agnes L. ANG, Haby HENARY, Gataree NGARMCHAMNANRITH
Abstract: A pharmaceutical formulation which comprises Compound 1, one or more pharmaceutical fillers, one or more pharmaceutical disintegrants, and one or more pharmaceutical lubricant.
Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
Type:
Application
Filed:
November 3, 2023
Publication date:
March 21, 2024
Inventors:
David KASS, Toru HASHIMOTO, Lawrence P. WENNOGLE, Joseph HENDRICK, Robert DAVIS
Abstract: Provided is a use of Wee1 kinase inhibitors in the treatment of cancer. In particular, provided is a use of Wee1 kinase inhibitors in the preparation of drugs for the treatment of cancers with Histone H3K27M mutation.
Type:
Application
Filed:
March 9, 2022
Publication date:
March 21, 2024
Inventors:
Ye Edward TIAN, Sui Xiong CAI, Mingchuan GUO, Chih-Yi HSIEH, Rong WANG, Ruiyu ZHOU
Abstract: This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K?.
Abstract: The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).
Type:
Application
Filed:
December 21, 2021
Publication date:
March 21, 2024
Applicant:
LG CHEM, LTD.
Inventors:
Hee Dong PARK, Su Jin YEO, Hyun Seo PARK, Jin Sook PARK, Hye Won AHN
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam or ibuprofen and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Type:
Application
Filed:
November 15, 2023
Publication date:
March 21, 2024
Inventors:
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
Type:
Application
Filed:
November 6, 2023
Publication date:
March 21, 2024
Applicant:
Antares Pharma, Inc.
Inventors:
Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jonathan Jaffe
Abstract: Methods for treating blood-brain barrier dysfunction and methods for treating recurrent seizures in a subject involve inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX), 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2).
Abstract: The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of temporal lobe epilepsy. In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-Cl at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
Type:
Application
Filed:
October 23, 2020
Publication date:
March 21, 2024
Inventors:
Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
Abstract: A method of treating a disease or pathology caused by an increase in levels of inflammatory cytokines comprising providing the subject with a compound of Formula I, (I) wherein, R1 is a C1-C20 branched or unbranched hydrocarbon; R3 is (II); or R4 is H or a pharmaceutically acceptable cation; R5 is a C1-C10 branched or unbranched hydrocarbon or optionally substituted with one or more groups; R6 is a C1-C10 branched or unbranched hydrocarbon or optionally substituted; R7 is a C0-C20 branched or unbranched hydrocarbon; R8 is H or a C0-C20 branched or unbranched hydrocarbon; X is a direct linkage, CH2, O or NH; Y is a direct linkage, CH2, O or NH; and, each stereogenic center is independently R, S or racemic.
Type:
Application
Filed:
January 21, 2022
Publication date:
March 21, 2024
Inventors:
Peter P. Sordillo, Dan Salvail, Sebastien M. Labbe
Abstract: The present disclosure relates to compounds and methods for preventing infection, symptoms, or sequelae resulting from viral infection, including influenza infection, rhinovirus infection, or betacoronavirus infection, such as human coronaviruses such as SARS coronaviruses, MERS coronaviruses, and COVID-19, including Acute Respiratory Distress Syndrome (ARDS) associated with the viral infection.
Type:
Application
Filed:
January 29, 2022
Publication date:
March 21, 2024
Inventors:
Ameer E. HASSAN, Yousef Hasan Ahmad KHALILI
Abstract: The present invention discloses a pharmaceutical composition comprising picroside isolated from Picrorhiza kurroa. The composition contains Picroside I as an active ingredient for treating drug-induced immunopathy such as neutropenia. Methods of isolating Picroside I and Picroside II, and preparing the compositions have also been disclosed herein. The said composition of Picroside I can be a solid oral or an injectable composition of a pre-determined dose. The said composition of Picroside I exhibited reversal of drug-induced immunopathy such as neutropenia through in vivo tests as well as in vitro tests. Therefore, it can be used as a herbal therapeutic agent for treating drug-induced immunopathy such as neutropenia.
Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
Type:
Application
Filed:
November 21, 2023
Publication date:
March 21, 2024
Inventors:
Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
Abstract: A method of treatment for coronavirus disease 2019 (COVID-19) is disclosed herein. The method comprises administering a therapeutically effective dose of a combination of ribavirin and minocycline. A pharmaceutical composition comprising ribavirin and minocycline is also disclosed herein. The pharmaceutical composition may further include one or more pharmaceutical excipients.
Abstract: The present invention relates to an inhibitor against the stem cells of chronic myeloid leukemia (CML), a pharmaceutical composition for the treatment of CML having preventive effect on CML recurrence, a method of preventing CML recurrence, and a method of assessing the efficacy of treatment with a drug in a patient with CML, including a step of determining the expression level of latexin.
Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
Type:
Application
Filed:
November 3, 2023
Publication date:
March 21, 2024
Applicants:
GENENTECH, INC., ABBVIE INC.
Inventors:
Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
Abstract: The present application relates to fractions from a root portion of an American ginseng (Panax quinquefolius) plant, and in particular, an intermediate polysaccharide fraction, a neutral polysaccharide fraction, an acidic polysaccharide rich fraction and an acidic polysaccharide fraction and to processes for their preparation, compositions comprising them, and to their use in therapy. For example, the fractions of the application are useful in the treatment of diseases, disorders or conditions treatable by activating pattern recognition receptors such as Toll-like receptors (TLR) or treatable by activating the innate and adaptive immune response, such as a viral infection.
Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
Abstract: The present invention relates to a veterinary supplement composition for preventing colic that includes simethicone and optionally sorbitol. The veterinary supplement composition is administered orally by syringe or mixed with animal feed. The veterinary supplement composition can be liquid or powder. Dosage is determined by body weight from about 1 mL per 400 pounds of body weight to about 1.2 mL per 400 pounds of body weight. Palatants can be added to improve animal taste likability. Such Palatants can include mint, apple, cinnamon, peppermint, banana, and others. The oral supplement can also be used in the prevention of colic in horses.
Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.
Type:
Application
Filed:
November 28, 2023
Publication date:
March 21, 2024
Inventors:
Paul Bundschuh, Lawrence Carlson, Shawn Dolan, Andrew M. Yaksic
Abstract: There is provided a Wnt agonist for use in preventing gastrointestinal tract cancer in a subject, wherein the subject has a genetic predisposition to gastrointestinal tract cancer such as FAP as well as a Wnt agonist for preventing or inhibiting the formation of intestinal pre-cancerous lesions or intestinal adenomas.
Type:
Application
Filed:
April 12, 2022
Publication date:
March 21, 2024
Inventors:
Sanne Marcella Maria Van Neerven, Louis Vermeulen
Abstract: The present invention provides methods of treating corneal astigmatism comprising administering composition comprising a copper-containing agent to an eye of a subject in need thereof.
Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.
Type:
Application
Filed:
October 17, 2023
Publication date:
March 21, 2024
Inventors:
Courtney Crane, Michael C. Jensen, Kara White Moyes, Nicole Lieberman
Abstract: Provided herein are methods of treatment including methods of treating cancer and methods of enhancing an anti-tumoral activity of a bispecific T-cell engager (BiTE) or of a bispecific antibody. The methods disclosed herein include activating T-cells and contacting activated T-cells with BiTEs or bispecific antibodies for administration to a subject.
Type:
Application
Filed:
December 10, 2021
Publication date:
March 21, 2024
Inventors:
Ivan M. Borrello, Amy Thomas, Eric L. Smith